Jul 27 2017 3
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
